- Home
- HCKT vs BCAX Comparison
HCKT vs BCAX Comparison
Compare HCKT & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- BCAX
- Stock Information
- Founded
- HCKT 1991
- BCAX 2018
- Country
- HCKT United States
- BCAX United States
- Employees
- HCKT N/A
- BCAX N/A
- Industry
- HCKT Professional Services
- BCAX
- Sector
- HCKT Consumer Discretionary
- BCAX
- Exchange
- HCKT Nasdaq
- BCAX NYSE
- Market Cap
- HCKT 789.8M
- BCAX 670.9M
- IPO Year
- HCKT 1998
- BCAX 2024
- Fundamental
- Price
- HCKT $29.17
- BCAX $13.40
- Analyst Decision
- HCKT Strong Buy
- BCAX Strong Buy
- Analyst Count
- HCKT 3
- BCAX 6
- Target Price
- HCKT $32.67
- BCAX $34.20
- AVG Volume (30 Days)
- HCKT 122.0K
- BCAX 608.4K
- Earning Date
- HCKT 05-06-2025
- BCAX 03-27-2025
- Dividend Yield
- HCKT 1.65%
- BCAX N/A
- EPS Growth
- HCKT N/A
- BCAX N/A
- EPS
- HCKT 1.05
- BCAX N/A
- Revenue
- HCKT $307,028,000.00
- BCAX N/A
- Revenue This Year
- HCKT $7.67
- BCAX N/A
- Revenue Next Year
- HCKT $4.54
- BCAX N/A
- P/E Ratio
- HCKT $27.86
- BCAX N/A
- Revenue Growth
- HCKT 5.41
- BCAX N/A
- 52 Week Low
- HCKT $20.23
- BCAX $11.10
- 52 Week High
- HCKT $34.02
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- HCKT 47.49
- BCAX N/A
- Support Level
- HCKT $28.23
- BCAX N/A
- Resistance Level
- HCKT $29.51
- BCAX N/A
- Average True Range (ATR)
- HCKT 0.63
- BCAX 0.00
- MACD
- HCKT 0.14
- BCAX 0.00
- Stochastic Oscillator
- HCKT 80.23
- BCAX 0.00
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.